SAN DIEGO, March 24, 2014 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology
company focused on delivering breakthrough 3D bioprinting
technology, announced today that Barry
Michaels, Chief Financial Officer, will present at the
2nd Annual Regen Med Investor Day to be held
Wednesday, March 26, 2014 in
New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in
partnership with leading financial firms Maxim Group and
Piper Jaffray, this one-day investor
conference focuses exclusively on the regenerative medicine and
advanced therapies sector. The event includes clinical and
commercial experts who will be on-hand to address specific
questions regarding the outlook for the industry, as well as offer
insight into how regenerative medicine products could impact the
standard of care in key therapeutic areas. The program will include
talks by key opinion leaders in the industry, life science
investment experts and analysts as well as presentations by more
than 30 leading companies from across the globe.
The following are specific details regarding Organovo's
presentation:
Event
Date:
|
March 26,
2014
|
|
|
Presentation
Time:
|
4:45 – 5:00
p.m.
|
|
|
Location:
|
West Lounge Room,
Metropolitan Club,
|
|
One East 60th Street,
New York, NY 10022
|
Attendance at this event is for credentialed investors and
members of the media only. If you are interested in attending,
please contact Laura Parsons at
lparsons@alliancerm.org. Please visit http://www.arminvestorday.com
for more information.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional
human tissues for medical research and therapeutic applications.
The Company is collaborating with pharmaceutical and academic
partners to develop human biological disease models in three
dimensions. These 3D human tissues have the potential to accelerate
the drug discovery process, enabling treatments to be developed
faster and at lower cost. In addition to numerous scientific
publications, the Company's technology has been featured
in The Wall Street Journal, Time Magazine, The Economist,
and numerous others. Organovo is changing the shape of
medical research and practice. Learn more
at www.organovo.com.
About the Alliance for Regenerative Medicine
The
Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder
advocacy organization that promotes legislative, regulatory and
reimbursement initiatives necessary to facilitate access to
life-giving advances in regenerative medicine and advanced
therapies. ARM also works to increase public understanding of the
field and its potential to transform human healthcare, providing
business development and investor outreach services to support the
growth of its member companies and research organizations. Prior to
the formation of ARM in 2009, there was no advocacy organization
operating in Washington, DC to
specifically represent the interests of the companies, research
institutions, investors and patient groups that comprise the entire
regenerative medicine community. Today ARM has more than 150
members and is the leading global advocacy organization in this
field. To learn more about ARM or to become a member, visit
www.alliancerm.org.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; and the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in our filings with
the SEC, including our prospectus supplement filed with
the SEC on November 27, 2013 and our transition
report on Form 10-KT filed with the SEC on May 24, 2013 as well as our other filings
with the Securities and Exchange Commission. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date that they were made. These cautionary
statements should be considered with any written or oral
forward-looking statements that we may issue in the future. Except
as required by applicable law, including the securities laws
of the United States, we do
not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
SOURCE Organovo Holdings, Inc.